

## **BREATHTEC BIOMEDICAL INC.**

Suite 890, 789 West Pender Street  
Vancouver, British Columbia, Canada V6C 1H2

### **Breathtec Biomedical Announces Plans for Breath Analysis Clinical Trials at Canadian Tech Facility**

**--City of Surrey's Health & Technology District to host Breathtec's in-licensed Na-Nose study for disease detection.**

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 28, 2016) - [Breathtec BioMedical, Inc.](#) (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the "**Company**" or "**Breathtec**"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases, is holding a press conference today to announce plans for the commencement of the company's clinical trial program at Innovation Boulevard located in Surrey, British Columbia.

Today's announcement marks the beginning of an intensive research review into NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion – Israel Institute of Technology which has been in-licensed by Breathtec. The system has been developed to detect the volatile biomarkers of diseases from exhaled breath, and Breathtec has chosen the Province of British Columbia and the City of Surrey to hold its clinical trials for selected respiratory infections at the Health & Technology District on Innovation Boulevard.

"Breathtec's exciting technology, developed in Israel, is going through the highest quality clinic trials right here in British Columbia," said Minister of Technology, Innovation and Citizens' Services, Amrik Virk. "We have a vibrant tech sector attracting companies from clean tech, to information and communications systems, to life sciences – this kind of innovative work is a key part of our diversified economy."

"The City of Surrey supports the development of health technologies and we welcome Breathtec Biomedical to our growing stable of health technology specialist firms," said Mayor Linda Hepner. "The addition of Breathtec is another example of how the City of Surrey is committed to working together to help take innovative science and technology ideas off the drawing board and turning them into real working solutions that will improve the quality of life for all."

Breathtec CEO, Mr. Guy LaTorre states, "We are delighted to come to the City of Surrey, British Columbia and to have the opportunity to access such a world-class facility and team. The Na-Nose device is an exciting new late stage technology that has already been clinically proven in the early detection of cancer and has the potential to change the way we diagnose respiratory diseases which will be our company's focus."

During the event, NA-NOSE lead researcher Professor Hossam Haick will demonstrate how the nanotechnology-based breath analysis system is used for screening of potentially life-threatening diseases. The licensed technology will be clinically evaluated as a non-invasive point of care device for early detection of community and hospital based infections such as Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold, etc.

**Press Conference** – Tuesday, June 28th at 11 a.m. (PDT), 2 pm (EDT).

**Where:** City Centre 1, 13737 96th Avenue, HealthTech Innovation Hub (2nd Floor), Surrey, Canada.

**In Attendance:**

- Honourable Minister Amrik Virk, Minister of Technology, Innovation and Citizens' Services
- Mayor Linda Hepner, City of Surrey

- Guy LaTorre, Chief Executive Officer, Breathtec Biomedical
- Dr. Hossam Haick, Professor in Chemical Engineering and Nanotechnology at Technion -Israel Institute of Technology (product demonstrations)
- Dr. Raj Attariwala, MD, PhD., Lead Engineer, Breathtec Biomedical

Innovation Boulevard is an agile partnership of health, business, higher education and government coming together and creating new health technologies to improve peoples' lives through a shared vision to achieve innovative results, improve health outcomes for patients, implement intelligent solutions for the health care economy, attract talented clinicians and researchers, and to grow companies in the health care technology and services sector. Find out more at: [www.innovationboulevard.ca](http://www.innovationboulevard.ca).

#### **ON BEHALF OF THE BOARD**

"Guy LaTorre"  
CEO & Director

#### **For further information, please contact:**

Kal Malhi  
President and Director  
[Breathtec BioMedical, Inc](http://BreathtecBioMedical.com)

or

Core Capital Partners  
Telephone: 604-566-9233  
Email: [investors@ccpartnersinc.com](mailto:investors@ccpartnersinc.com)

*CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release.*

*This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*

